Oral GLP-1 drugs may quiet the brain’s food craving circuit
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Virginia researchers found that oral GLP-1 drugs orforglipron and danuglipron reduced pleasure-driven eating in mice by activating the central amygdala and suppressing dopamine release in the brain's reward system — a pathway distinct from the hypothalamus and hindbrain circuits tied to hunger-driven eating.
- NIDA Clinical Director Lorenzo Leggio said that as patient uptake of these medications rises, "it's crucial that we understand the neural mechanisms underlying the effects we're seeing."
- Co-corresponding author Ali Guler (UVA biology professor) noted the drugs "dial back eating for pleasure by engaging a brain reward circuit," in addition to suppressing appetite.
- To make the mouse model more translatable, the team used gene-editing to modify GLP-1 receptors in mice to more closely resemble human receptors before administering the drugs.
- Orforglipron is FDA-approved as an oral GLP-1 pill, while danuglipron remains experimental; both are small-molecule drugs that researchers say can be taken as pills and may cost less to manufacture than injectable semaglutide-based drugs like Ozempic, Wegovy, and Rybelsus.
- Published in Nature (2026, Vol. 654) and funded by four NIH institutes, the team announced plans for follow-up studies testing whether the drugs can reduce cravings tied to substance use disorder.
Why it matters: The finding gives oral GLP-1 drugs a second mechanistic leg to stand on beyond appetite suppression, hinting at future research into substance use disorder. Patients could also benefit: orforglipron is already FDA-approved as a pill, potentially offering a cheaper, needle-free alternative to injectable Ozempic-class drugs.
